Publications by authors named "P R Sieber"
Article Synopsis
- The importance of germline genetic testing (GGT) for prostate cancer patients has grown, as it helps tailor treatment plans and manage the disease more effectively.
- GGT is now considered a standard practice not just for prostate cancer, but also for other cancers like breast and ovarian, emphasizing the need for all patients to have equitable access to this testing.
- Offering comprehensive GGT allows for better decision-making between patients and doctors, aids in detecting potential future cancers, and facilitates testing for family members who may be at risk.
What Is This Summary About?: Advanced prostate cancer is a cancer that began in the prostate (a part of the male body) and has spread to other parts of the body. This is a review of two clinical research studies of patients with advanced prostate cancer who were treated with relugolix combination therapy. Relugolix is a medicine taken by mouth that lowers a male sex , called testosterone.
View Article and Find Full Text PDFMalodorants comprise notoriously smelling mercaptans and might be applied for crowd control. Because exposure to malodorants may lead to irritation of the respiratory system, choking, and coma, bioanalytical verification of poisoning might be required in a medical and forensic context. We herein present the detection and identification of novel biomarkers of exposure to ethyl mercaptan, n-butyl mercaptan, tert-butyl mercaptan, and iso-amyl mercaptan.
View Article and Find Full Text PDFArticle Synopsis
- Recent clinical trials indicate that combining PARP inhibitors with novel hormonal therapy can improve progression-free survival in men with metastatic prostate cancer, leading to new approvals for this treatment by regulatory bodies in several countries.
- * The study utilized the RAND/UCLA Delphi method, involving a panel of 12 experts who reviewed literature and rated management options for adverse events (AEs) arising from treatment across 419 patient scenarios.
- * Key findings showed a significant reduction in disagreement among experts on AE management strategies, with consensus on approaches for managing mild, moderate, and severe AEs, enhancing guidance for clinical decision-making.
Background: Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are encountering increasingly challenging clinical scenarios, with limited guidance from the current literature.
Materials And Methods: The US Prostate Cancer Conference (USPCC) is a multidisciplinary meeting of prostate cancer experts intended to address the many challenges of prostate cancer management.